About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

339,504 studies
in
214 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/04/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/04/2020.
  • Isocitrate Dehydrogenase (IDH) Mutations

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

     

    The isocitrate dehydrogenase (IDH) proteins are critical enzymes in the Krebs cycle, which is central to many biochemical pathways.1-3 IDH occurs in 3 isoforms: IDH1, IDH2, and IDH3.1,3 All IDH isoforms catalyze the conversion of isocitrate to α-ketoglutarate (α-KG)—but in different cellular compartments.3,4 IDH1 is found in the cytoplasm and peroxisomes, whereas IDH2 and IDH3 are found in the mitochondria.3,4  It is hypothesized that IDH1 and IDH2 mutations may initiate and drive cancer growth by blocking the differentiation of primitive cells.5,6 Cancer-associated IDH3 mutations have not been reported.

    Acquiring a somatic mutation in either IDH1 or IDH2 can confer gain-of-function activity in cancer cells, which may result in accumulation of the oncometabolite 2-hydroxyglutarate (2-HG).5,6 In preclinical studies, cancer cells with mutated IDH1/2 have elevated 2-HG levels, resulting in an increase in the inhibition of DNA and histone demethylating enzymes that utilize α-KG, such as tet methylcytosine dioxygenase 2 (TET2) and lysine (K)-specific demethylase (KDM).7-9 Elevated 2-HG levels associated with mutant IDH1/2 can lead to global changes in DNA and histone methylation, impairment of cellular differentiation, and potential tumorogenesis.6-10 Preclinical studies suggest that inhibiting gain-of-function mutant IDH1/2 prevents the excess production of 2-HG and may restore cellular differentiation.9,11-13

    Mutations to either IDH1 or IDH2 have been observed in multiple cancers, including acute myeloid leukemia (AML), grade II/III glioma and secondary glioblastoma, chondrosarcoma, intrahepatic cholangiocarcinoma, angioimmunoblastic T cell lymphoma, thyroid carcinoma, and myelodysplastic syndromes (MDS).14-16

    2-HG, 2-hydroxyglutarate; α-KG, α-ketoglutarate; IDH, isocitrate dehydrogenase; KDM, lysine (K)-specific demethylase; TET2, tet methylcytosine dioxygenase 2.

    View Related Molecules

    References

    1. Reitman ZJ, Yan H. J Natl Cancer Inst. 2010;102:932-941. PMID: 20513808
    2. Raimundo N, et al. Trends Mol Med. 2011;17:641-649. PMID: 21764377
    3. Losman JA, Kaelin WG Jr. Genes Dev. 2013;27:836-852. PMID: 23630074
    4. Krell D, et al. Future Oncol. 2013;9:1923-1935. PMID: 24295421
    5. Ward PS, et al. Cancer Cell. 2010;17:225-234. PMID: 20171147
    6. Figueroa ME, et al. Cancer Cell. 2010;18:553-567. PMID: 21130701
    7. Cardaci S, Ciriolo MR. Int J Cell Biol. 2012;2012:161837. PMID: 22888353
    8. Krall AS, Christofk HR. Nature. 2013;496:38-40. PMID: 23552939
    9. Losman JA, et al. Science. 2013;339:1621-1625. PMID: 23393090
    10. Turcan S, et al. Nature. 2012;483:479-483. PMID: 22343889
    11. Rohle D, et al. Science. 2013;340:626-630. PMID: 23558169
    12. Kernytsky A, et al. Blood. 2015;125:296-303. PMID: 25398940
    13. Wang F, et al. Science. 2013;340:622-626. PMID: 23558173
    14. Cairns RA, Mak TW. Cancer Discov. 2013;3:730-741. PMID: 23796461
    15. Yang H, et al. Clin Cancer Res. 2012;18:5562-5571. PMID: 23071358
    16. Thol F, et al. Haematologica. 2010; 95:1668-1674. PMID: 20494930